Genta Announces Promotion of Dr. Loretta M. Itri to President, Pharmaceutical Development
BERKELEY HEIGHTS, N.J., May 27, 2003 /PRNewswire-FirstCall via COMTEX/ -- Genta
Incorporated (Nasdaq: GNTA) announced today that Loretta M. Itri, M.D.,
F.A.C.P., formerly Executive Vice-President, Clinical Research and Development,
has been appointed President, Pharmaceutical Development. She replaces Dr.
Raymond P. Warrell, Jr. in the role of President, who remains Chairman and Chief
Executive Officer. The Pharmaceutical Development group is comprised of the
Departments of Clinical Research & Development, Regulatory Affairs, Quality
Control, Preclinical Development, Project Management, and Manufacturing.
"Prior to this appointment, Dr. Itri had assumed a central coordinating role in
the NDA filings for the Company's lead products, Ganite and Genasense," said Dr.
Warrell. "Her leadership has been a key factor in Genta's progress to date, and
we look forward to continued benefit from her contributions in this key
executive role."
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product
portfolio that is focused on delivering innovative products for the treatment of
patients with cancer. The Company's research platform is anchored by two
programs that center on oligonucleotides (DNA/RNA-based medicines) and small
molecules. Genasense(TM) (oblimersen sodium) is the Company's lead compound from
its oligonucleotide program and is currently undergoing late-stage, Phase 3
clinical testing. The leading drug in Genta's small molecule program is
Ganite(TM) (gallium nitrate injection), which the Company intends to launch
later this year for treatment of cancer-related hypercalcemia that is resistant
to hydration. For more information about Genta, please visit our website at:
www.genta.com. |
